Increasing Rates of Fluoroquinolone Resistance in Escherichia coli Blood and Urinary Isolates in Stem Cell Transplant and Hematologic Malignancy Populations
Article Sidebar
Main Article Content
Abstract
Fluoroquinolone (FQ) antibiotics have been shown to reduce mortality and the number of febrile episodes when used as prophylaxis during neutropenia. Prior studies suggest that prophylaxis may result in increasing rates of FQ resistance. Fluoroquinolone non-susceptibility trends in Escherichia coli isolated from blood and urine cultures were evaluated over a 16-year period during which prophylaxis was initiated in patients with hematologic malignancies and stem cell transplants. Non-susceptibility rates increased after the introduction of prophylaxis, with yearly non-susceptibility rates rising from 30%–33% to 40%–88% in blood isolates. The high rates of non-susceptibility now observed raise concerns about the continued efficacy of FQ prophylaxis. This concern exists particularly in those patients undergoing stem cell transplants where the total FQ non-susceptibility rates over the study period were 82.3%. Further evaluation of the effect of FQ prophylaxis on antibiotic resistance and its efficacy in the setting of increased rates of resistance is warranted.
Downloads
Article Details
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant. 2007;40(1):63-70. PubMed PMID: 216653881; 17468772. doi: 10.1038/sj.bmt.1705690
2. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, di Grazia C, Frassoni F, Bacigalupo A, Viscoli C. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15(1):47-53. PubMed PMID: 19135942. doi: 10.1016/j.bbmt.2008.10.024
3. Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, Kiehn TE, Pamer E, Papanicolaou GA. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7(1):11-7. doi: 10.1111/j.1399-3062.2005.00088.x
4. Busca A, Cavecchia I, Locatelli F, D'Ardia S, De Rosa FG, Marmont F, Ciccone G, Baldi I, Serra R, Gaido E, Falda M. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis. 2012;14(1):40-8. PubMed PMID: 21599817. doi: 10.1111/j.1399-3062.2011.00650.x
5. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, Incidence, and Susceptibility of Bacterial Bloodstream Isolates from 519 Bone Marrow Transplant Patients. Clin Infect Dis. 2001;33(7):947-53. doi: 10.1086/322604
6. Ninin E, Milpied N, Moreau P, André-Richet B, Morineau N, Mahé B, Vigier M, Imbert B-M, Morin O, Harousseau J-L, Richet H. Longitudinal Study of Bacterial, Viral, and Fungal Infections in Adult Recipients of Bone Marrow Transplants. Clin Infect Dis. 2001;33(1):41-7. doi: 10.1086/320871
7. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977-87. PubMed PMID: 16148283. doi: 10.1056/NEJMoa044097
8. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142(12 Pt 1):979-95. PubMed PMID: 15968013.
9. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young J-AH, Wingard JR. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi: 10.1093/cid/cir073
10. Recommendations of the Center for International Blood and Marrow Transplant Research (CIBMTR®) tNMDPN, the European Blood and Marrow Transplant Group (EBMT), the American Society of Blood and Marrow Transplantation (ASBMT), the Canadian Blood and Marrow Transplant Group (CBMTG), the Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the Association of Medical Microbiology and Infectious Diseases Canada (AMMI), and the Centers for Disease Control and Prevention (CDC), , Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143-238. PubMed PMID: 19747629. Pubmed Central PMCID: 3103296. doi: 10.1016/j.bbmt.2009.06.019
11. Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy. 2011;57(4):335-8. PubMed PMID: 21912115. doi: 10.1159/000329661
12. Therriault BL, Wilson JW, Barreto JN, Estes LL. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc. 2010;85(8):711-8. PubMed PMID: 20675508. Pubmed Central PMCID: 2912731. doi: 10.4065/mcp.2010.0006
13. De Rosa FG, Motta I, Audisio E, Frairia C, Busca A, Di Perri G, Marmont F. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis. 2013;13:563. PubMed PMID: 24289496. Pubmed Central PMCID: PMC4219399. doi: 10.1186/1471-2334-13-563
14. Macesic N, Morrissey CO, Cheng AC, Spencer A, Peleg AY. Changing microbial epidemiology in hematopoietic stem cell transplant recipients: increasing resistance over a 9-year period. Transpl Infect Dis. 2014;16(6):887-96. PubMed PMID: 25298044. doi: 10.1111/tid.12298
15. Miles-Jay A, Butler-Wu S, Rowhani-Rahbar A, Pergam SA. Incidence rate of fluoroquinolone-resistant gram-negative rod bacteremia among allogeneic hematopoietic cell transplantation patients during an era of levofloxacin prophylaxis. Biol Blood Marrow Transplant. 2015;21(3):539-45. PubMed PMID: 25498393. Pubmed Central PMCID: PMC4329069. doi: 10.1016/j.bbmt.2014.12.006
16. Chong Y, Yakushiji H, Ito Y, Kamimura T. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis. 2011;15(4):e277-81. PubMed PMID: 21324723. doi: 10.1016/j.ijid.2010.12.010
17. Simondsen KA, Reed MP, Mably MS, Zhang Y, Longo WL. Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2013;19(4):291-7. PubMed PMID: 23184539. doi: 10.1177/1078155212465215